Topic
What conditions beyond weight and diabetes might GLP-1s treat?
Kidney disease, heart failure, sleep apnea, Alzheimer's and other emerging GLP-1 uses, explained from sourced research.
Microdosing Semaglutide: What It Means, Whether It Works, and Safety"Microdosing" semaglutide means taking doses below what the FDA approved and studied, often without medical supervision. There is no official definition or dose, no robust clinical evidence it works, and weight loss at very low doses tends to be modest, around 5% to 6%.Microdosing Zepbound: What the Evidence Actually ShowsMicrodosing Zepbound has no clinical definition, and clinicians say there is no robust evidence it works at very small doses. The label approves 5, 10, or 15 mg weekly for maintenance, and SURMOUNT-MAINTAIN found 5 mg held weight loss at −16.6% versus −9.9% for placebo.Ozempic Babies: Why Unexpected Pregnancies Happen on GLP-1s"Ozempic babies" are unexpected pregnancies in people taking GLP-1 drugs, mostly because weight loss restores ovulation. Semaglutide has not been shown to weaken the pill, but tirzepatide cut pill hormone levels by up to 66%, and the Wegovy label says to stop at least 2 months before a planned pregnancy.Semaglutide Alzheimer's Trial Results: What EVOKE ShowedNo. In two phase 3 trials of 3,808 people with early Alzheimer's, oral semaglutide did not slow disease progression on the primary CDR-SB endpoint or any secondary measure, though some biomarkers improved. Topline results were announced 24 November 2025.Semaglutide and Alcohol Cravings: What the Research ShowsYes—early trial evidence points that way. Three small randomized trials report fewer heavy drinking days on semaglutide, including a 41.1% drop in one 26-week trial, though craving results are mixed. It is not FDA-approved for alcohol use disorder, and larger trials are still needed.Semaglutide for PCOS: What the Research Actually ShowsSemaglutide is not FDA-approved for PCOS. Two small Chinese trials found adding it to metformin improved weight loss and menstrual-cycle recovery versus metformin alone; one reported a 35% vs. 15% natural pregnancy rate. Prescribing among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025.Tirzepatide and Heart Failure: What the SUMMIT Trial ShowedIn the SUMMIT trial, tirzepatide cut the combined risk of cardiovascular death or worsening heart failure by 38% (HR 0.62) in adults with HFpEF and obesity, but neither Zepbound nor Mounjaro is approved for heart failure in the US or EU.Tirzepatide for PCOS: Evidence, Approval, and Pregnancy RisksTirzepatide (Mounjaro/Zepbound) is not FDA-approved for PCOS. One small 16-week trial found 10.4 kg weight loss and 53.6% menstrual recovery when added to metformin, but a larger placebo-controlled trial is still recruiting.What Else Can Semaglutide Treat Besides Weight Loss?FDA-approved semaglutide uses go beyond weight loss: type 2 diabetes, cardiovascular risk reduction, chronic kidney disease (Ozempic, added January 28, 2025), and fatty liver disease (Wegovy, August 15, 2025). Heart failure, sleep apnea, and Alzheimer's are not approved uses.What Else Can Tirzepatide Treat? Approved and Studied UsesTirzepatide (Mounjaro, Zepbound) is FDA-approved for type 2 diabetes, weight loss, sleep apnea, and — since August 2026 — reducing heart attack and stroke risk in adults with diabetes at high risk. Heart failure, diabetes prevention, and fatty liver show positive trials but no approval.Zepbound for Sleep Apnea: What the Evidence Actually ShowsZepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. In 52-week trials it cut AHI by about 20-24 events per hour versus placebo, but sleep medicine groups say it is a tool alongside CPAP, not a replacement.